Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

• Published in: Cell transplantation Vol. 30; p. 963689721996649
• Main Authors: Wang, Tianyi, Feng, Mingxuan, Luo, Chengjuan, Wan, Xinyu, Pan, Ci, Tang, Jingyan, Xue, Feng, Yin, Minzhi, Lu, Dongqing, Xia, Qiang, Li, Benshang, Chen, Jing
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 2021; Sage Publications Ltd; SAGE Publishing
• Subjects: Antigens; Autografts; Biliary atresia; Burkitt's lymphoma; CD19 antigen; Chemotherapy; Cyclophosphamide; Cytokines; Epstein-Barr virus; Fludarabine; Immunosuppressive agents; Immunotherapy; Liver transplantation; Liver transplants; Lymphocytes; Lymphocytes B; Lymphocytes T; Lymphoma; Monoclonal antibodies; Neonates; Neurotoxicity; Original; p53 Protein; Paraffin; Patients; Pediatrics; Posttransplant lymphoproliferative disorders; Remission; Stem cell transplantation; Transplants & implants; Tumors; PTLD; CAR T-cells; CD19; Burkitt lymphoma

In the immunocompromised setting, recipients of solid-organ or hematopoietic stem-cell transplants carry an increased risk of post-transplant lymphoproliferative disorder (PTLD). Burkitt lymphoma (BL) PTLD is a rare form of monomorphic B-cell PTLD, which lacks a standard best treatment. Here, we rep...